Aldafermin

NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout. What Happened California-based NGM, which IPOed last March, announced positive preliminary top-line results from Cohort 4 of an adaptive Phase 2 study that...